Current Report Filing (8-k)
March 22 2017 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington D.C.
20549
Form
8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report
(Date of earliest event reported): March 21,
2017
INNOVUS
PHARMACEUTICALS, INC.
(Exact name of registrant as
specified in its charter)
Nevada
|
000-52991
|
90-0814124
|
(State or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS Employer Identification
No.)
|
9171 Towne Centre Drive, Suite 440,
San Diego, CA
|
|
92122
|
(Address of Principal Executive
Offices)
|
|
(Zip Code)
|
Registrant’s telephone
number, including area code:
(858)
964-5123
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
☐
|
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR
230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
In this report, “Innovus
Pharmaceuticals,” “Innovus Pharma,” “the
Company”, “we,” “us” and
“our” refer to Innovus Pharmaceuticals, Inc., and/or
one or more of our wholly-owned subsidiaries, unless the context
otherwise provides. Innovus Pharma® is a registered service
mark of Innovus Pharmaceuticals, Inc.
Item 7.01
– Regulation FD Disclosure
Item 8.01
– Other Events
On March 22, 2017, the Company
issued a press release reporting that the Company has repaid all of
its outstanding convertible notes. The full text of the press
release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
Item 9.01 --
Financial Statements and Exhibits
(d)
Exhibits
Exhibit
Number
|
Description
|
99.1
|
Press release issued March 22,
2017, reporting that the Company has repaid all of its outstanding
convertible notes.
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly
caused
this
Report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
INNOVUS
PHARMACEUTICALS, INC
|
|
|
|
|
|
Date
: March 22,
2017
|
By:
|
/s/ ROBERT E. HOFFMAN
|
|
|
|
Robert E.
Hoffman
|
|
|
|
Executive Vice President, Chief
Financial Officer
|
|
EXHIBIT INDEX
Exhibit
Number
|
Description
|
99.1
|
Press release issued March 22,
2017, reporting that the Company has repaid all of its outstanding
convertible notes.
|